Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study

Journal of Health Economics

Volumn 25, Issue 6, 2006, Pages 1015-1028

  Thompson, Simon G ^a   Nixon, Richard M ^a   Grieve, Richard ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cost data; Generalised linear models; Health economic evaluation; Hierarchical models; Multinational studies

Indexed keywords

COST-BENEFIT ANALYSIS; DATA ACQUISITION; HEALTH EXPENDITURE; HETEROGENEITY; NUMERICAL MODEL; SKEWNESS; STATISTICAL DISTRIBUTION;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COVARIANCE; DATA ANALYSIS; DATA COLLECTION METHOD; HEALTH CARE COST; HEALTH CENTER; NORMAL DISTRIBUTION; PATIENT CODING; RANDOMIZATION; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL;

COSTS AND COST ANALYSIS; GREAT BRITAIN; INTERNATIONALITY; MODELS, STATISTICAL; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC;

EID: 33750023687     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2006.02.001     Document Type: Article

References (53)

1. Austin P.C., Ghali W.A., and Tu J.V. A comparison of several regression models for analysing cost of CABG surgery. Statistics in Medicine 22 (2003) 2799-2815
2. Barber J.A., and Thompson S.G. Multiple regression of cost data: use of generalised linear models. Journal of Health Services Research and Policy 9 (2004) 197-204
3. Basu A., and Rathouz P.J. Estimating marginal and incremental effects on health outcomes using flexible link and variance function parameters. Biostatistics 6 (2005) 93-109
4. Basu A., Manning W.G., and Mullahy J. Comparing alternative models: log vs. Cox proportional hazard?. Health Economics 13 (2004) 749-765
5. Bernt E. International comparisons of pharmaceutical prices: what do we know, and what does it mean?. Journal of Health Economics 19 (2000) 283-287
6. Blundell R., and Windmeijer F. Cluster effects and simultaneity in multilevel models. Health Economics 6 (1997) 439-443
7. Briggs A., and Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. Journal of Health Services Research and Policy 3 (1998) 233-245
8. Burgess J.E., Cristiansen C.L., Michalak S.E., and Morris C.N. Medical profiling: improving standards and risk adjustments using hierarchical models. Journal of Health Economics 19 (2000) 291-309
9. Carey K. A multi-level modelling approach to analysis of patient costs under managed care. Health Economics 9 (2000) 435-446
10. Clayton D., and Hills M. Statistical Models in Epidemiology (1993), Oxford University Press, Oxford
11. Cook J.R., Drummond M., Glick H., and Heyse J.F. Assessing the appropriateness of combining economic data from multinational clinical trials. Statistics in Medicine 22 (2003) 1955-1976
12. Coyle D., and Drummond M.F. Analyzing differences in the costs of treatment across centres within economic evaluations. International Journal of Technology Assessment in Health Care 17 (2001) 155-163
13. Danzon P., and Chao L.W. Cross-national price differences for pharmaceuticals: how large, and why?. Journal of Health Economics 19 (2000) 159-195
14. Dodd S., Bassi A., Bodger K., and Williamson P. A comparison of multivariable regression models to analyse cost data. Journal of Evaluation in Clinical Practice 12 (2006) 76-86
15. Drummond M.F., Bloom B.S., Carrin G., et al. Issues in the cross-national assessment of health technology. International Journal of Technology Assessment in Health Care 8 (1992) 671-682
16. Gelman A., Carlin J.B., Stern H.S., and Rubin D.B. Bayesian Data Analysis (2004), Chapman and Hall, London
17. Gilks W.R., Richardson S., and Spiegelhalter D.J. Markov Chain Monte Carlo in Practice (1996), Chapman and Hall, London
18. Glick H.A., Willke R., Polsky D., et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. International Journal of Technology Assessment in Health Care 14 (1998) 145-160
19. Goldstein H. Multilevel Statistical Models (1995), Edward Arnold, London
20. Grieve R., Dundas R., Beech R., and Wolfe C.D.A. The development and use of a method to compare the costs of acute stroke across Europe. Age and Ageing 30 (2001) 67-72
21. Grieve R., Hutton J., Bhalla A., et al. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke 32 (2001) 1684-1691
22. Grieve R., Nixon R.M., Thompson S.G., and Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Economics 14 (2005) 185-196
23. Hardy R.J., and Thompson S.G. Detecting and describing heterogeneity in meta-analysis. Statistics in Medicine 17 (1998) 841-856
24. Heitjan D.F., Kim C.Y., and Li H. Bayesian estimation of cost-effectiveness from censored data. Statistics in Medicine 23 (2004) 1297-1309
25. Johannesson M., Jonsson B., Kjekshus J., et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine 303 (1997) 332-336
26. Jones A.M. Health econometrics. In: Culyer A.J., and Newhouse J.P. (Eds). Handbook of Health Economics 1 (2000), Elsevier, Amsterdam
27. Kavanos P., and Mossialos E. International comparisons of health care expenditures: what we know and what we do not know. Journal of Health Services Research and Policy 4 (1999) 122-126
28. Kilian R., Matschinger H., Loeffler W., Roick C., and Angermeyer M.C. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment. Journal of Mental Health Policy and Economics 5 (2002) 21-31
29. Lee A.H., Gracey M., Wang K., and Yau K.K. A robustified modeling approach to analyze pediatric length of stay. Annals of Epidemiology 15 (2005) 673-677
30. In: Leyland A.H., and Goldstein H. (Eds). Multi-level Modelling of Health Statistics (2001), Wiley, Chichester
31. Localio A.R., Berlin J.A., Ten Have T.R., and Kimmel S.E. Adjustments for center in multicenter studies: an overview. Annals of Internal Medicine 135 (2001) 112-123
32. Manca A., Rice N., Sculpher M.J., and Briggs A.H. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics 14 (2005) 471-485
33. Manning W.G., and Mullahy J. Estimating log models: to transform or not to transform?. Journal of Health Economics 20 (2001) 461-494
34. Mark D.B., Flatky M.A., Califf R.M., et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New England Journal of Medicine 332 (1995) 1418-1424
35. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. Journal of Health Economics 17 (1998) 247-281
36. Newhouse J. Frontier estimation: how useful a tool for health economics?. Journal of Health Economics 13 (1994) 317-322
37. Nixon R.M., and Thompson S.G. Parametric modelling of cost data in medical studies. Statistics in Medicine 23 (2004) 1311-1331
38. Nixon R.M., and Thompson S.G. Incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Economics 14 (2005) 1217-1229
39. O'Brien B.J. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. The American Journal of Managed Care 3 (1997) S33-S39
40. O'Hagan A., and Stevens J.W. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?. Health Economics 12 (2003) 33-49
41. Or Z., Wang J., and Jamison D. International differences in the impact of doctors on health: a multilevel analysis of OECD countries. Journal of Health Economics 24 (2005) 531-560
42. Phelps C.E., and Mooney C. Variations in medical practice use, causes and consequences. In: Arnoud R.J., Rich R.F., and White W.D. (Eds). Competitive Approaches to Health Care Reform (1993), The Urban Institute Press, Washington, DC 139-178
43. Pinto E.M., Willan A.R., and O'Brien B.J. Cost-effectiveness analysis for multinational clinical trials. Statistics in Medicine 24 (2005) 1965-1982
44. Raikou M., Briggs A., Gray A., and McGuire A. Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Economics 9 (2000) 191-198
45. Schulman K., Buxton M., Glick H., et al. Results of the economic evaluation of the first study. A multinational prospective economic evaluation. International Journal of Technology Assessment in Health Care 12 (1996) 698-713
46. Seshamani M., and Gray A.M. A longitudinal study of the effects of age and time to death on hospital costs. Journal of Health Economics 23 (2004) 217-235
47. Spath H.-M., Carrere M.-O., Fervers B., and Philip T. Analysis of the eligibility of published economic evaluations for transfer to a given health care system: Methodological approach and application to the French health care system. Health Policy 49 (1999) 161-177
48. Thompson S.G. Why sources of heterogeneity in meta-analysis should be investigated. British Medical Journal 309 (1994) 1351-1355
49. Thompson S.G., and Barber J.A. How should cost data in pragmatic randomised trials be analysed?. British Medical Journal 320 (2000) 1197-1200
50. Thompson S.G., and Nixon R.M. How sensitive are cost-effectiveness analyses to choice of parametric distributions?. Medical Decision Making 25 (2005) 416-423
51. Willan A.R., Pinto E.M., O'Brien B.J., et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrunken estimation: the Canadian ASSENT-3 economic analysis. Health Economics 14 (2005) 327-338
52. Willke R.J., Glick H.A., Polsky D., and Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Economics 7 (1998) 481-493
53. Wordsworth S., and Ludbrook A. Comparing costing results in across-country economic evaluations: the use of technology-specific purchasing power parity. Health Economics 14 (2004) 93-99